UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): September 27, 2011

 

REDPOINT BIO CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-51708

 

22-3393959

(State of Incorporation)

 

(Commission File No.)

 

(IRS Employer ID No.)

 

Redpoint Bio Corporation

7 Graphics Drive

Ewing, New Jersey 08628

(Address of Principal Executive Offices)

 

(609) 637-9700

Registrant’s Telephone Number, Including Area Code:

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02.              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 27, 2011, Redpoint Bio Corporation, a Delaware corporation (the “Company”), mutually agreed with F. Raymond Salemme, Ph.D. (“Dr. Salemme”), the Company’s President and Chief Executive Officer, that Dr. Salemme shall resign as the Company’s President and Chief Executive Officer, effective immediately.  Dr. Salemme will continue to participate as a member of the Company’s board of directors.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

REDPOINT BIO CORPORATION

 

 

Dated: October 3, 2011

 

 

 

 

By:

/s/ Scott Horvitz

 

Name:

Scott Horvitz

 

Title:

Chief Financial Officer, Treasurer and Secretary

 

3